medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2015, Número 3

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (3)


TRALI, una amenaza enmascarada: biología y fisiopatología

Rmán TR, Fernández DND, Trujillo PHJ

Idioma: Español
Referencias bibliográficas: 56
Paginas: 226-241
Archivo PDF: 164.90 Kb.


RESUMEN

El daño pulmonar agudo ocasionado por la transfusión o TRALI (por sus siglas en inglés), definido como la aparición de un distrés respiratorio agudo en un paciente recién transfundido, pasó de ser considerado una complicación infrecuente de la terapia transfusional a ser actualmente la principal causa de mortalidad por transfusión, según sistemas de hemovigilancia de Europa y Norteamérica. Su desarrollo en forma clínicamente reconocible se atribuye a la interacción entre factores dependientes de la unidad transfundida (tipo de componente, presencia de sustancias biológicamente activas, etc.) y el estado de las respuestas celulares en el receptor. La heterogeneidad en cuanto al cuadro clínico de los pacientes afectados, la variación en el volumen infundido, el tipo de componente implicado y el tiempo desde el inicio de la transfusión hasta la aparición de los síntomas, ha hecho evolucionar la explicación a la génesis de este evento adverso, en el afán de incluir los casos sin explicación mediante las distintas hipótesis. Dos interesantes acercamientos patogénicos resultan la teoría de “dos golpes” y el modelo basado en el umbral que impone la relación entre los distintos factores de riesgo. La naturaleza multicausal del TRALI y el sinnúmero de variables que pueden influir en su aparición y reconocimiento, continúan haciendo de este un reto médico importante en el contexto de la medicina transfusional, donde su mejor enfoque terapéutico sigue siendo el preventivo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Popovsky MA, Abel MD, Moore SB. Transfusion related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Resp Dis. 1983;128:185-9.

  2. Keller-Stanislawski B, Reil A, Günay S, Funk MB. Frequency and severity of transfusion-related acute lung injury-German hemovigilance data (2006-2007). Vox Sang. 2010;98:70-7. doi:10.1111/j.1423-0410.2009.01232.x

  3. Funk MB, Günay S, Lohmann A, Henseler O, Heiden M, Hanschmann KMQ, et al. Benefit of transfusion-related acute lung injury risk-minimization measures-German hemovigilance data (2006-2010). Vox Sang. 2012;102:317-23. doi:10.1111/j.1423-0410.2011.01556.x

  4. Chapman CE, Stainsley D, Jones H, Love E, Massey E, Win N, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kindom, and the impact of preferential use of male donor plasma. Transfusion. 2009;49:440-52.

  5. Toy P, Gajic O, Bachetti P, Looney MR, Grooper MA, Hubmayr RD; for the TRALI Study Group. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757-67.

  6. Ozier Y, Muller JY, Mertes PM, Renaudier P, Aguilon P, Canivet N, et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion. 2011;51:2102-10. doi: 10.1111/j.1537- 2995.2011.03073.x

  7. Moore SB. Transfusion-related acute lung injury (TRALI). Clinical presentation, treatment and prognosis. Crit Care Med. 2006;34(5):114-7.

  8. Marik PE, Corwin HL. Acute lung injury following to transfusion: Expanding the definition. Crit Care Med. 2008;36:3080-4.

  9. Triulzi DJ. Transfusion-Related Acute Lung Injury: Current Concepts for the Clinician. J Anest Analg. 2009;108(3):770-6. doi: 10.1213/ane.0b013e31819029b2.

  10. Kleinman S, Caufield T, Chan P, Davenport R, McFarland J, McPhedran S, et al. Toward an understanding of transfusion-related acute lung injury: statements of a consensus panel. Transfusion. 2004;44:1774-89.

  11. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards and understanding of TRALI. Transfus Med Rev. 2005;19:2-31.

  12. Añón JM, García de Lorenzo A, Quintana M, González E, Bruscas M. Lesión pulmonar aguda producida por transfusión. Med Intens. 2010;34(2):139-149. doi: 10.1016/i.medin.2009.03.007.

  13. Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet.2013;382:984-94. DOI:10.1016/S0140-6736(12)62197-7.

  14. Román-Torres R, Fernández-Delgado N, Trujillo-Puentes H. TRALI, una amenaza enmascarada: definición, aspectos epidemiológicos y clínicos. Rev Cubana Hematol Inmunol Hemoter [revista en Internet]. 2014 [citado 2014 Sep 2];31(1): Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/177

  15. Vlaar AP, Porcelijn L, van Rooijen-Schreurs IH, Lardy NM, Kersten MJ, Juffermans NP. The divergent clinical presentations of transfusion-related acute lung injury illustrated by two case reports. Med Sci Monit. 2010;16(10):CS129-34.

  16. Benson AB, Austin GL, Berg M. Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med. 2010;36(10):1710-7.

  17. Vlaar AP, Bimekade JM, Prins D, van Stein D, Hofstra JJ, Schultz MJ, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med. 2010;38:771-8.

  18. Benjamin RJ. Tracking TRALI in target populations. Blood. 2011;117(16):4163- 4. doi:10.1182/blood-2011-03-338913.

  19. Sahz BH. Givin TRALI the one-two punch. Blood. 2012;119:1620-1. doi:10.1182/blood-2011-12-395897.

  20. Juffermans NP. Transfusion-related acute lung injury: emerging importance of host factors and implications for management. Expert Rev Hematol. 2010;3(4):459-67.

  21. Popovsky MA, Abel MD, Moore SB. Transfusion related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Resp Dis. 1983;128:185-9.

  22. Fung YL, Silliman CC. The role of neutrophils in the pathogenesis of transfusionrelated acute lung injury. Transfus Med Rev. 2009;23(4):266-83.

  23. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol. 2007;5(8):577-82.

  24. López MR, Cortina L. Daño pulmonar agudo relacionado con la transfusión. Rev Cubana Hematol Inmunol Hemoter. [revista en la Internet]. 2005 Ago [citado 2014 Sep 02]; 21(2): Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892005000200005&lng=es

  25. Lazzerini G, Del Turco S, Basta G , O'Loghlen A, Zampolli A, Caterina RD. Prominent role of NF-kappaB in the induction of endothelial activation by endogenous nitric oxide inhibition. Nitric Oxide. 2009 Nov-Dec; 21(3-4):184-91. doi:10.1016/j.niox.2009.07.007.

  26. Bozza FA, Shah AM, Weyrich AS, Zimmermann GA. Amicus or adversary: platelets in lung biology, acute injury and inflammation. Am J Respir Cell Mol Biol. 2009;40(2):123-34. doi: 10.1165/rcmb.2008-0241TR.

  27. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-5.

  28. Caudrillier A, Kessenbrock K, Gillis BM, Nguyen JX, Marques MB, Monestier M, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122(7):2661-71.

  29. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105:2266-73. doi:10.1182/blood-2004-07-2929.

  30. Storch EK, Hillyer CD, Shaz BH. Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. Blood. 2014 Sep 18;124(12):1868-72.

  31. Sahler J, Spinelli R, Phipps R, Blumberg N. CD40 ligand (CD154) involvement in platelet transfusion reactions. Transfus Clin Biol. 2012 Jun;19(3):98-103. doi: 10.1016/j.tracli.2012.02.003.

  32. Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of leukocyte antibody screening of blood donors. Vox Sang. 2008;95:313-7.

  33. Quillen K, Medrano C, Adams S, Peterson B, Hackett J, Leitman SF, et al. Screening plateletpheresis donors for HLA antibodies on two high throughput platforms and correlation with recipient outcome. Transfusion. 2011;51:504-10.

  34. Davoreen A, Curtis BR, Schulman IA, MohrbacherAF, Bux J, Kwiatkowska BJ, et al. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a(5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion. 2003;43:641-5.

  35. Müller MCA, Juffermans NP. Transfusion-related acute lung injury: a preventable syndrome? Expert Rev Hematol. 2012;5(1):97-106.

  36. Greinacher A, Wesche J, Hammer E. Characterization of the human neutrophil alloantigen-3a. Nat Med. 2010;16(1):45-8.

  37. Curtis BR, Cox NJ, Sullivan MJ. The neutrophil alloantigen HNA-3a(5b) is located on choline transporter-like protein 2 and appears to be encoded by an R>Q154 aminoacid substitution. Blood. 2010;115(10):2073-6.

  38. Bowens KL, Sullivan MJ, Curtis BR. Determination of neutrophil antigen HNA-3a y HNA-3b genotype frequencies in six racial groups by high-throughput 5´exonuclease assay. Transfusion. 2012;52(11):2368-74.

  39. Flesch BK, Wesche J, Berthold T. Expression of the CTL2 transcript variants in human peripheral blood cells and human tissues. Transfusion. 2013;53(12):3217-23.

  40. Bayat B, Tjahjono Y, Sydykov A. Anti-human neutrophil antigen-3a induced transfusión-related acute lung injury in mice by direct disturbance of lung endotelial cells. Arterioscler Thromb Vasc Biol. 2013;33(11):2538-48.

  41. Kleinman S, Triulzi DJ, Murphy EL, Carey PM, Gottschall JL, Roback JD, et al. For the National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (REDS-II). The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or negative components. Transfusion. 2011; 51:2078-91. doi:10.1111/j.1537-2995.2011.03120.x

  42. Win N, Chapman CE, Bowles KM, Green A, Bradley S, Edmondson D, et al. How much residual plasma may cause TRALI? Transf Med. 2008;18:276-80. doi:10.1111/j.1365-3148-2008.00885.x

  43. Segel GB, Halterman MW, Lichtman MA. The paradox of the neutrophil´s role in tissue injury. J Leukoc Biol. 2011;89(3):359-72.

  44. Middelburg RA, Borkent B, Jansen M, van de Watering LMG, Wiersum-Osselton JC, Schipperus MR, et al. Storage time of blood products and transfusion-related acute lung injury. Transfusion. 2012;52:658-67 doi:10.1111/j.1537-2995.2011.03352.x.

  45. Vlaar AP, Hofstra JJ, Levi M. Supernatant of aged erythrocytes causes lung inflammation and coagulopathy in a `two hit´ in vivo syngeneic transfusion model. Anesthesiology. 2010;13(1):92-103.

  46. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455-62. doi:10.1182/blood-2006-07-034736.

  47. Stronceck DF. Hot on the trail of TRALI. Blood. 2006;108(7):2136-7. doi:10.1182/blood-2006-07-034736.

  48. Silliman CC, Moore SB, Kelher MR, Khan SY, Gellar L, Elzi DJ. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion. 2011;51(12):2549-54.

  49. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils trough CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455-62.

  50. Rizvi M, Pathak D, Freedman JE, Chakrabarti S. CD40-CD40L interactions in oxidative stress, inflammantion and vascular disease. Trends Mol Med. 2008;14(12):530-8.

  51. Apelseth TO, Hervig T, Wentzel-Larsen T, Petersen K, Reikvam H, Bruseurd O. A prospective observational study of the effect of platelet transfusion on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. Eur Cytokine Netw. 2011;22(1):52-62.

  52. Wenzel F, Günter W, Baertl A, Gruber W, Sorg RV, Haas R, et al. Platelet transfusion alters CD40L blood level and release capacity in patients suffering from thrombocytopenia. Transfusion. 2011;51(12):2549-54.

  53. Bakry R, Sayed D, Galal H, Shaker S. Platelet function, activation and apoptosis during and after apheresis. Ther Apher Dial. 2010;14(5):457-64.

  54. Cognasse F, Payrat JM, Corash L, Osselaer JC, Garraud O. Platelet components associated with acute transfusion reactions: the role of platelet-derived soluble CD40 ligand. Blood. 2008;112(12):4779-80.

  55. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, et al. Plateletmediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Inmunity. 2003;19(1):9-19.

  56. Tuinman PR, Gerards MC, Jongsma G, Vlaar AP, Boon L, Juffermans NP. Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. Clin Exper Inmunol. 2011;165(2):278-84.




2020     |     www.medigraphic.com